Core formulation comprising troglitazone and abiguanide

Details Core formulation comprising troglitazone and abiguanide Core formulation comprising troglitazone and abiguanide

2000-10-31

2001-10-02

Spear, James M. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S468000, C424S471000, C424S475000, C424S490000, C514S866000

Reexamination Certificate

active

06296874

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a core formulation, and, more particularly, to a core formulation comprising a first layer comprising troglitazone, which covers at least a portion of a core comprising a biguanide, such as for example metformin (i.e., glucophage).
2. Description of the Related Art
Metformin and troglitazone, and their salts such as the hydrochlorides, maleates, tartrates, etc., are two active ingredients of anti-diabetic drugs that are used to treat diabetic patients, e.g. human beings. These two active agents are administered orally to patients in need thereof in protocols calling for the single administration of either ingredient. Heretofore, there has not been revealed or hinted at combining both ingredients and certainly not a physically combined core formulation comprising both ingredients. The advantage of such a core formulation is advantageous to patients and prescribers because both medicaments are synergistic to each other in the body when used in the management of blood glucose control, i.e., diabetes.
SUMMARY OF THE INVENTION
This invention relates to a core formulation, and, more particularly, to a core formulation comprising a first layer comprising troglitazone or a derivative thereof, e.g. troglitazone hydrochloride, which covers at least a portion of a core comprising a biguanide. A typical biguanide is metformin. It typically is used clinically as a pharmaceutically acceptable salt, preferably the hydrochloride salt. A commercial form of metformin hydrochloride is available as glucophage. Its chemical name is N,N-dimethylimidodicarbonimidic diamide hydrochloride. Metformin hydrochloride is a hydrochloride salt of metformin base, and as used herein, “metformin” means the base compound as well as its pharmaceutically acceptable salts. Metformin is used clinically to manage non-insulin dependent diabetes mellitus (“NIDDM”), particularly in patients who are not effectively treated with a sulfonylurea. While it is not chemically related to the sulfonylureas, it is routinely utilized in combination with a sulfonylurea, and has been shown to be synergistic in some cases. Other biguanides such as phenformin, buformin etc. can also be used. Additionally, in the treatment of a diabetic patient the metformin and the troglitazone, e.g. its hydrochloride, are present in effective amounts to A provide such treatment.


REFERENCES:
patent: 6011049 (2000-01-01), Whitcomb
patent: 6031004 (2000-02-01), Timmins et al.
patent: 6166042 (2000-12-01), Ikeda et al.

Affiliated with

Also associated with

Rating

Core formulation comprising troglitazone and abiguanide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Core formulation comprising troglitazone and abiguanide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Core formulation comprising troglitazone and abiguanide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2615117